View full meeting coverage »

Eyetube Meeting Coverage:

2018 AECOS Summer Symposium



Your 25-second video preview has ended.

to continue watching, please Log In or Register:

Log in / Register

Innovation on the Horizon: Nasal Spray for Dry Eye

  Channels: General | Posted 7/14/2018

Jeff Nau, PhD, summarizes the latest data on Oyster Point Pharma's novel dry eye disease treatment, OC-02, a nicotinic acetylcholine receptor that is delivered via the trigeminal parasympathetic pathway. Dr. Nau explains the drug's mechanism of action and the early results of the PEARL study, a phase 2b randomized clinical trial.

Dry Eye

1 / 12 Series: 2018 AECOS Summer Symposium